Table 3.
Allo-HCT and auto-HCT response characteristics
| Allo-HCT | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Anti–SARS-CoV-2 spike IgG | Neutralizing Abs | ||||||||||
| Variable | Group | N | Median (IQR) | <50 | >50 | P | N | Median (IQR) | <30% | >30% | P |
| Time groups per type of cellular treatment | Early allo | 19 | 445.6 (112.3–5,728.2) | 4 (21%) | 15 (79%) | 0.282 | 14 | 74.9 (12.3–95.7) | 5 (36%) | 9 (64%) | 0.341 |
| Mid-allo | 55 | 3,409.3 (683.8–20,901.2) | 6 (11%) | 49 (89%) | 49 | 88.5 (46.5–96.3) | 10 (20%) | 39 (80%) | |||
| Late allo | 75 | 6,786.6 (1,833.5–17,535.7) | 6 (8%) | 69 (92%) | 61 | 94.6 (60.3–96.3) | 11 (18%) | 50 (82%) | |||
| CD4 count | <200 | 21 | 422.6 (13.2–2,247.2) | 6 (29%) | 15 (71%) | 0.016 | 16 | 53.7 (2–93.3) | 7 (44%) | 9 (56%) | 0.019 |
| ≥200 | 81 | 6,651.7 (1,258–20,281.6) | 6 (7%) | 75 (93%) | 71 | 95.5 (64.6–96.4) | 11 (15%) | 60 (85%) | |||
| CD19 count | <50 | 13 | 27.5 (5.2–373.2) | 7 (54%) | 6 (46%) | <0.001 | 10 | 0 (0–20.7) | 8 (80%) | 2 (20%) | <0.001 |
| ≥50 | 89 | 6,425.7 (1,258–20,281.6) | 5 (6%) | 84 (94%) | 77 | 95.5 (67.4–96.3) | 10 (13%) | 67 (87%) | |||
| IgG level | <500 | 18 | 1,156.5 (373.4–24,333.3) | 4 (22%) | 14 (78%) | 0.038 | 15 | 49.3 (12.9–96) | 5 (33%) | 10 (67%) | 0.133 |
| ≥500 | 78 | 6,538.7 (1,257.1–20,457.2) | 4 (5%) | 74 (95%) | 68 | 94.7 (66.7–96.3) | 10 (15%) | 58 (85%) | |||
| All immune criteria for vaccination met prior to COVID-19 vaccine | Not met | 35 | 916.5 (115.8–19,124) | 7 (20%) | 28 (80%) | 0.002 | 29 | 61 (7.5–96.2) | 11 (38%) | 18 (62%) | 0.002 |
| Met | 48 | 7,638 (2,322.9–20,340.1) | 0 (0%) | 48 (100%) | 43 | 95.7 (87.5–96.4) | 3 (7%) | 40 (93%) | |||
| Immune suppression with tacrolimus/cyclosporine or ruxolitinib | Yes | 46 | 4,430.4 (319–15,835.9) | 5 (11%) | 41 (89%) | >0.99 | 40 | 89.3 (18.1–96.1) | 13 (32%) | 27 (68%) | 0.036 |
| No | 103 | 5,019.8 (936.8–17,529.2) | 11 (11%) | 92 (89%) | 84 | 94.6 (56.6–96.3) | 13 (15%) | 71 (85%) | |||
| Steroids | Yes | 21 | 543.9 (16.1–5,786.1) | 7 (33%) | 14 (67%) | 0.002 | 16 | 21 (0–74) | 9 (56%) | 7 (44%) | 0.001 |
| No | 128 | 5,960.4 (952–20,340.1) | 9 (7%) | 119 (93%) | 108 | 95.1 (56.6–96.4) | 17 (16%) | 91 (84%) | |||
| Auto-HCT | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Anti–SARS-CoV-2 spike IgG | Neutralizing Abs | ||||||||||
| Variable | Group | N | Median (IQR) | <50 | >50 | P | N | Median (IQR) | <30% | >30% | P |
| Time groups per type of cellular treatment | Early auto | 20 | 718 (16.1–6,300.1) | 7 (35%) | 13 (65%) | 0.001 | 15 | 44.8 (0–83.2) | 7 (47%) | 8 (53%) | 0.025 |
| Late auto | 41 | 2,512.3 (673–10,598.8) | 1 (2%) | 40 (98%) | 37 | 85.9 (52.3–96.3) | 5 (14%) | 32 (86%) | |||
| CD4 count | <200 | 6 | 242 (35.4–407.9) | 2 (33%) | 4 (67%) | 0.612 | 4 | 30.1 (12.8–53.5) | 2 (50%) | 2 (50%) | 0.557 |
| ≥200 | 23 | 2,390.8 (407–9,879.6) | 5 (22%) | 18 (78%) | 19 | 80.5 (15.6–96.4) | 5 (26%) | 14 (74%) | |||
| CD19 count | <50 | 9 | 10.5 (4.4–419.4) | 6 (67%) | 3 (33%) | 0.001 | 6 | 15.6 (0–41.4) | 3 (50%) | 3 (50%) | 0.318 |
| ≥50 | 20 | 3,123.9 (901.1–9,520.1) | 1 (5%) | 19 (95%) | 17 | 80.5 (41.6–96.3) | 4 (24%) | 13 (76%) | |||
| IgG level | <500 | 14 | 487 (28.4–1,143.3) | 4 (29%) | 10 (71%) | 0.091 | 12 | 59.2 (1.8–79.1) | 4 (33%) | 8 (67%) | 0.433 |
| ≥500 | 35 | 2,645.4 (584.9–10,405.8) | 3 (9%) | 32 (91%) | 30 | 79.4 (46–95.1) | 6 (20%) | 24 (80%) | |||
| All immune criteria for vaccination met prior to COVID-19 vaccine | Not met | 13 | 554.5 (21.2–2,390.8) | 4 (31%) | 9 (69%) | 0.327 | 44.8 (18.1–82.9) | 3 (27%) | 8 (73%) | >0.99 | |
| Met | 11 | 3,602.3 (1,403.2–8,277.5) | 1 (9%) | 10 (91%) | 86.6 (53.8–96.3) | 2 (22%) | 7 (78%) | ||||
| IMiDs | Yes | 20 | 1,176.6 (417.3–3,370.1) | 2 (10%) | 18 (90%) | >0.99 | 19 | 59 (12.2–88.1) | 6 (32%) | 13 (68%) | 0.317 |
| No | 41 | 2,757.1 (419.4–21,010.8) | 6 (15%) | 35 (85%) | 33 | 85.9 (51.5–96.5) | 6 (18%) | 27 (82%) | |||
| Daratumumab | Yes | 12 | 513 (226.6–1,486.9) | 1 (8%) | 11 (92%) | >0.99 | 11 | 59 (8.9–81.4) | 4 (36%) | 7 (64%) | 0.253 |
| No | 49 | 3,292.7 (655–19,499) | 7 (14%) | 42 (86%) | 41 | 80.5 (44.8–96.3) | 8 (20%) | 33 (80%) | |||